Phase 2 Open-Label Trial Investigating Percutaneous Laser Ablation for Treatment of Early-Stage Breast Cancer: MRI, Pathology, and Outcome Correlations

Schwartzberg, Barbara S.; Lewin, John M.; Abdelatif, Osama; Bernard, Jacqueline; Bu-Ali, Hanadi; Cawthorn, Simon; Chen-Seetoo, Margaret; Feldman, Sheldon; Govindarajulu, Srinivas; Jones, Lyn; Juette, Arne; Kavia, Sanjay; Maganini, Robert; Pain, Simon; Shere, Mike; Shriver, Craig D.; Smith, Simon; Valencia, Alexandra; Whitacre, Eric; Whitney, Roger

doi:10.1245/s10434-018-6623-2

Cited by 27 publications

(19 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MRI is a sensitive image for diagnosis of the breast lesion (24). It has been used to predict tissue damage after BC ablation, and previous studies suggested MRI was suitable for long-term follow-up of ablation of BC with a NPV of 92.2-97.7% (25)(26)(27). MRI evaluated the efficacy of MWA with the NPV of 100% and specificity of 95.8% in our study.…”

Section: Discussionmentioning

confidence: 67%

Microwave Ablation Versus Nipple Sparing Mastectomy for Breast Cancer ≤5 cm: A Pilot Cohort Study

Han

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Objectives Compared with nipple sparing mastectomy (NSM), microwave ablation (MWA) is one relatively new modality indicated for selected breast cancer with nipple sparing and with little of evidence-based medical research for decision-making. The objective of this study was to compare the effect of ultrasound-guided percutaneous MWA and NSM for breast cancer. Materials and Methods A retrospective cohort study was conducted in a single institution from 2014 to 2020. Women with invasive ductal carcinoma of the breast ≤ 5cm treated by MWA or NSM were enrolled. The primary end point was tumor progression and secondary end points included survival, cosmetic results, and complications. Results 21 patients in the MWA group and 43 in the NSM group were evaluated. The mean tumor size was 2.3 cm (range, 0.3–5.0 cm). Median follow-up was 26.7 months (range, 14.6–62.5 months). The mean age of MWA was 24 years older than that of the NSM group. All the patients achieved technique effectiveness. One local tumor progression and one ipsilateral breast recurrence occurred at 42 and 28 months after MWA, respectively. One ipsilateral breast recurrence and two bone metastasis occurred at 31.2, 34, and 30.5 months after NSM. Two groups had no significant difference in tumor progression (P = 0.16). No participants in both groups developed cancer related death (P > 0.99) and major complications (P > 0.99). However, MWA needed less hospitalization time (P < 0.001) and achieved better cosmetic results (P < 0.001). Conclusions MWA achieved similar short term effect for breast cancer control and better cosmetic satisfaction compared with NSM in selected patients. MWA provides appropriate option for elderly patients who are unfit for surgery.

show abstract

Section: Discussionmentioning

confidence: 67%

Microwave Ablation Versus Nipple Sparing Mastectomy for Breast Cancer ≤5 cm: A Pilot Cohort Study

Han

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Imaging Techniques. MRI had a higher negative predictive value than US and mammography, respectively 92%, 89%, and 75% in 1 study, 17 and was not reported in other studies.…”

Section: Laser Ablationmentioning

confidence: 58%

“…In none of the studies the patient or physician was blinded, and in only 3 studies the pathology review was done by central review or by at least 2 independent pathologists. [17][18][19] A sample size calculation or estimation was given in only 5 studies 11 , 20-24 (Appendix D).…”

Section: Quality Of Included Studiesmentioning

confidence: 99%

Thermal Ablation as an Alternative for Surgical Resection of Small (≤ 2 cm) Breast Cancers: A Meta-Analysis

Voort

Struik

Birnie

et al. 2021

Clinical Breast Cancer

View full text Add to dashboard Cite

“…[1,2] With the widespread availability of laser therapy devices in clinics, PTT attracts increasing interests of clinicians and patients due to its promising potential for effective treatment and minimized side effects. [3][4][5] However, advance of PTT for adoption in clinical cancer treatment is photosensitizers are NP size and surface chemistry. The NPs must be small so that they can be injected into the bloodstream, delivered to the tumor sites, and excreted through the renal and hepatic systems.…”

Section: Introductionmentioning

confidence: 99%

Starch Capped Atomically Thin CuS Nanocrystals for Efficient Photothermal Therapy

Zheng

Cao

et al. 2021

Small

View full text Add to dashboard Cite

hampered to date by the limited success in the development of clinical photothermal therapy agents. [6] PTT exploits heat generated locally by a photosensitizer, [7] in which both the photothermal agents and laser sources, as well as the matching between them, are essential. Laser thermal therapy generally employs continuouswave lasers with wavelengths of either 808 or 980 nm. [8,9] The wavelengths are in the near-IR (NIR, λ = 700-1100 nm) window so that photons can penetrate deep into biological tissue. [10][11][12] Certain nanoparticles (NPs) have proper carrier densities enabling them to exhibit localized surface plasmon resonances (LSPRs) that efficiently facilitate the conversion of NIR light into heat. [10][11][12] Several types of NPs are currently being developed as photosensitizers, including metallic and semiconductor NPs. Noble metal NPs, for example, Ag and Au NPs, have been extensively applied for the LSPRs in the visible spectrum. [5,[13][14][15] Semi conductor NPs have tunable carrier concentration and LSPRs typically in the NIR range. [10,11] A high photothermal conversion efficiency is key to effective NP photosensitizers to avoid thermal damage to healthy tissue, which is a serious problem in PTT. The NPs with a high photothermal conversion efficiency and tumor selectivity can thus effectively destroy the cancer cells at a low photon density and in a short treatment time, while keeping the surrounding healthy tissue at a safe temperature. [16] Other key factors to consider for developing Photothermal therapy requires efficient plasmonic nanomaterials with small size, good water dispersibility, and biocompatibility. This work reports a one-pot, 2-min synthesis strategy for ultrathin CuS nanocrystals (NCs) with precisely tunable size and localized surface plasmon resonance (LSPR), where a single-starch-layer coating leads to a high LSPR absorption at the near-IR wavelength 980 nm. The CuS NC diameter increases from 4.7 (1 nm height along [101]) to 28.6 nm (4.9 nm height along [001]) accompanied by LSPR redshift from 978 to 1200 nm, as the precursor ratio decreases from 1 to 0.125. Photothermal temperature increases by 38.6 °C in 50 mg L −1 CuS NC solution under laser illumination (980 nm, 1.44 W cm −2 ). Notably, 98.4% of human prostate cancer PC-3/Luc+ cells are killed by as little as 5 mg L −1 starch-coated CuS NCs with 3-min laser treatment, whereas CuS NCs without starch cause insignificant cell death. LSPR modeling discloses that the starch layer enhances the photothermal effect by significantly increasing the free carrier density and blue-shifting the LSPR toward 980 nm. This study not only presents a new type of photothermally highly efficient ultrathin CuS NCs, but also offers in-depth LSPR modeling investigations useful for other photothermal nanomaterial designs.

show abstract

Phase 2 Open-Label Trial Investigating Percutaneous Laser Ablation for Treatment of Early-Stage Breast Cancer: MRI, Pathology, and Outcome Correlations

Cited by 27 publications

References 11 publications

Microwave Ablation Versus Nipple Sparing Mastectomy for Breast Cancer ≤5 cm: A Pilot Cohort Study

Microwave Ablation Versus Nipple Sparing Mastectomy for Breast Cancer ≤5 cm: A Pilot Cohort Study

Thermal Ablation as an Alternative for Surgical Resection of Small (≤ 2 cm) Breast Cancers: A Meta-Analysis

Starch Capped Atomically Thin CuS Nanocrystals for Efficient Photothermal Therapy

Contact Info

Product

Resources

About